Source: Investing.com Stock Market ↗

Insmed stock rises on FDA priority review for Arikayce

|

Translation unavailable. Please try again.

Original report

Read the original report on Investing.com Stock Market ↗

Recommended markets

No specific asset was identified in this report; browse live USDT reference pairs.

Browse markets →

USDC/USDT

$1.00

-0.01%

BTC/USDT

$86,282.45

+0.65%

ETH/USDT

$2,752.90

+0.10%

ZEC/USDT

$1,590.96

+8.03%

XRP/USDT

$1.58

+4.37%